Many a biotechnology company can tell war stories of negative Phase III data, followed by analyst downgrades and a decline in stock price. But Onyx Pharmaceuticals Inc. had what is arguably an even more frustrating tale to tell: positive Phase III data, followed by an analyst downgrade and a decline in stock price. (BioWorld Today)